|
[1]CHEN JG.Trends in the incidence of liver cancer and its primary prevention in China[J].J Clin Hepatol, 2012, 28 (4) :256-260. (in Chinese) 陈建国.中国肝癌发病趋势和一级预防[J].临床肝胆病杂志, 2012, 28 (4) :256-260.
|
|
[2]TANG ZY.21st century:challenges facing the clinical research of liver cancer[J].J Clin Hepatol, 2012, 28 (4) :241-242. (in Chinese) 汤钊猷.21世纪肝癌临床面临的挑战[J].临床肝胆病杂志, 2012, 28 (4) :241-242.
|
|
[3] ELLIS LM, HICKLIN DJ.VEGF-targeted therapy:mechanisms of anti-tumour activity[J].Nat Rev Cancer, 2008, 8 (8) :579-591.
|
|
[4] LLOVET JM, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (4) :378-390.
|
|
[5]CHENG AL, KANG YK, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncol, 2009, 10 (1) :25-34.
|
|
[6]ANDERSON R, JATOI A, ROBERT C, et al.Search for evidence-based approaches for the prevention and palliation of hand–foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs) [J].Oncologist, 2009, 14 (3) :291-302.
|
|
[7]ROBERT C, SORIA JC, SPATZ A, et al.Cutaneous side-effects of kinase inhibitors and blocking antibodies[J].Lancet Oncol, 2005, 6 (7) :491-500.
|
|
[8]AUTIER J, ESCUDIER B, WECHSLER J, et al.Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor[J].Arch Dermatol, 2008, 144 (7) :886-892.
|
|
[9]SCHUTZ F, JE Y, RICHARDS C, et al.Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors[J].J Clin Oncol, 2012, 30 (8) :871-877.
|
|
[10]SIVENDRAN S, LIU Z, PORTAS LJ JR, et al.Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors:A meta-analysis[J].Cancer Treatment Reviews, 2012, 38 (7) :919-925.
|
|
[11]JE Y, SCHUTZ F, CHOUEIRI TK.Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib:a systematic review and meta-analysis of clinical trials[J].Lancet Oncol, 2009, 10 (10) :967-974.
|
|
[12]HERNON M, HOYERT DL, MURPHY SL, et al.Deaths:Final data for 2006[J].Natl Vital Stat Rep, 2009, 57 (14) :1-134.
|
|
[13]National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0[S/OL].[2006-08-09].http://ctep.cancer.gov/.
|
|
[14]IAVARONE M, CABIBBO G, PISCAGLIA F, et al.Field-practice study of sorafenib therapy for hepatocellular carcinoma:A prospective multicenter study in Italy[J].Hepatology, 2011, 54 (6) :2055-2063.
|
|
[15]CHU D, LACOUTURE ME, FILLOS T, et al.Risk of hand-foot skin reaction with sorafenib:a systematic review and meta-analysis[J].Acta Oncol, 2008, 47 (2) :176-186.
|
|
[16]ROBERT C, MATEUS C, SPATZ A, et al.Dermatologic symptoms associated with the multikinase inhibitor sorafenib[J].J Am Acad Dermatol, 2009, 60 (2) :299-305.
|
|
[17]AZAD NS, Aragon-Chin JB, Dahut WL, et al.Hand-Foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy[J].Clin Cancer Res, 2009, 15 (4) :1411-1416.
|
|
[18]LEE JH, CHUNG YH, KIM JA, et al.Genetic predisposition of Hand-Foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma[J].Cancer, 2012, 119 (1) :136-142.
|
|
[19]MIR O, CORIAT R, BOUDOU-ROUQUETTE P, et al.Sorafenib-induced diarrhea and hypophosphatemia:mechanisms and therapeutic implications[J].Ann Oncol, 2012, 23 (1) :280-281.
|
|
[20]ZHAO Y, YANG M, QI X, et al.Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma[J].Hepatology, 2012, 56 (2) :790-791.
|
|
[21]SONG T, ZHANG W, WU Q, et al.A single center experience of sorafenib in advanced hepatocellular carcinoma patients:evaluation of prognostic factors[J].Eur J Gastroenterol Hepatol, 2011, 23 (12) :1233-1238.
|
|
[22] LUO XN, LU LG, SHAO PJ, et al.Relationship between sorafenibassociated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma[J].Natl Med J China, 2012, 92 (13) :889-893. (in Chinese) 罗小宁, 陆骊工, 邵培坚, 等.索拉菲尼治疗中晚期肝癌相关的手足皮肤反应与疗效的关系[J].中华医学杂志, 2012, 92 (13) :889-893.
|
|
[23] VINCENZI B, SANTINI D, RUSSO A, et al.Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib[J].Oncologist, 2010, 15 (1) :85-92.
|
|
[24]OTSUKA T, EGUCHI Y, KAWAZOE S, et al.Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib[J].Hepatol Res, 2012, 42 (9) :879-886.
|
|
[25]ESTFAN B, BYRNE M, KIM R.Sorafenib in advanced hepatocellular carcinoma:hypertension as a potential surrogate marker for efficacy[J].Am J Clin Oncol, 2013, 36 (4) :319-324.
|
|
[26]BETTINGER D, SCHULTHEISS M, KNPPEL E, et al.Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma[J].Hepatology, 2012, 56 (2) :789-790.
|
|
[27]KAMBA T, MCDONALD DM.Mechanisms of adverse effects of antiVEGF therapy for cancer[J].Bri J Cancer, 2007, 96 (12) :1788-1795.
|
DownLoad: